Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib
Open Access
- 30 June 2020
- journal article
- case report
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 48 (6)
Abstract
Epidermal growth factor receptor (EGFR) gene-mutated non-small cell lung cancer may initially respond to EGFR tyrosine kinase inhibitors (TKIs), but may subsequently become resistant; however, the resistance mechanisms remain unclear. We report a rare case of acquired resistance to osimertinib associated with transformation to small cell lung cancer (SCLC) with cis-C797S mutation. A man with recurrent lung adenocarcinoma harboring an EGFR exon 19 deletion received erlotinib for 10 months following curative surgery and adjuvant chemotherapy. However, he switched to osimertinib after repeat biopsy showed EGFR exon 19 deletion and T790M mutation leading to erlotinib resistance. His disease progressed after 15 months and repeat biopsy showed SCLC. Next-generation sequencing of peripheral blood detected EGFR exon 19 deletion, T790M mutation, cis-C797S mutation, and RB1 inactivation. The tumor was reduced after four cycles of etoposide and cisplatin and his respiratory symptoms improved. However, computed tomography after six cycles of chemotherapy showed multiple bilateral lung lesions, and single-photon emission computed tomography showed bone metastasis. The patient received paclitaxel plus cisplatin for two cycles with partial response. Because heterogeneous genetic and phenotypic mechanisms of TKI-resistance may occur at different times and locations, histopathological and molecular testing both provide evidence to support appropriate treatment.Keywords
This publication has 22 references indexed in Scilit:
- Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case ReportCase Reports in Oncology, 2018
- Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsyLung Cancer, 2018
- Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung CancerJournal of Medicinal Chemistry, 2017
- Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at ResistanceJournal of Thoracic Oncology, 2017
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung AdenocarcinomasJournal of Clinical Oncology, 2017
- Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case reportOncotarget, 2017
- Cancer treatment and survivorship statistics, 2016CA: A Cancer Journal for Clinicians, 2016
- Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 TreatmentJournal of Thoracic Oncology, 2016
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNature Medicine, 2015
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015